A 2-AG Enzyme Review Distinguished Total Brain Activity From Cellular Location
A review of MAGL, ABHD6 and ABHD12 explained why their relative contribution to total brain 2-AG breakdown does not fully describe their local signaling role. Where an enzyme acts can matter alongside how much activity it contributes.
The review described different positions in the circuit
MAGL was discussed near presynaptic cannabinoid signaling, while neuronal ABHD6 was positioned near postsynaptic 2-AG generation. These locations support different proposed roles in terminating or limiting signals. A whole-brain activity percentage cannot identify every local effect.
Acute and sustained inhibition differed
The synthesis described acute MAGL inhibition increasing 2-AG and cannabinoid-related responses, while sustained inactivation could produce overload, desensitization and tolerance. A short-term increase in signaling does not establish a durable treatment benefit.
Uncertainty remained for another enzyme
The review discussed ABHD12 and its disease association while questioning its precise status within endocannabinoid signaling. A reported hydrolysis contribution does not settle every physiological role. That uncertainty should remain visible rather than making all three enzymes interchangeable targets.
Interpreting the evidence
The source supports interpreting enzyme amount, cellular position and exposure duration together. It is a mechanistic review, not evidence that manipulating any 2-AG enzyme safely reproduces marijuana effects or provides a validated clinical tolerance strategy.
Related reading: interpreting cannabis tolerance claims.
Research reference
Savinainen JR; Saario SM; Laitinen JT (2012). The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta physiologica (Oxford, England). doi:10.1111/j.1748-1716.2011.02280.x.
This analysis draws on the supplied review abstract.
